Ann: AVITA - Approval of New RECELL System Improved Ease of Use, page-28

They can always sell product to private patients and as long as product provides value against traditional method then it will be able to achieve sell over the time but they needs to try pushing for it. EU is bigger then GB so sure they can try other territories.

Even in Australia people use it for cosmetic treatment so hard to believe they can't sell product in UK & EU. It's call for removal of CEO at the helm to make it work for shareholders in my opinion.

https://www.lasersandlifts.com.au/treatments-i-do/recell/

See below screenshot of another small medical device company in Australia which I don't own stock in, but showing comparison that with 21.9m revenue they can make it profitable while Avita makes revenue of 29m and pay more to executive.. .look at 2020 payout for Perry and accountant within company.




Now, Avita has 14m worth of sales & marketing expense and 22.4m of administration expense... lol. (ignore research expense as it vastly different). Basically since 2019, 2020 and 2021 Avita made loss of 26+42+25 = 93m which probably close to 100m they collected.. lol ... !




There are 12 KMP and some of them in job since 2012 which is around 10 year so almost more then a government employee can work in one team for that long.. ! Reduce this to 6, reduce marketing and administration expense to 50% and you will get positive cashflow company... so it is opportunity for efficient operator who works on KPI and delivers... IMO. Vanguard and Blackrock are on top 20 shareholders but surprisingly they are keeping the board in job after this type of cost ... !